MODIFICATION
88 -- Live Animals
- Notice Date
- 4/16/2004
- Notice Type
- Modification
- NAICS
- 112990
— All Other Animal Production
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute of Allergy & Infectious Diseases/AMOB, 10401 Fernwood Drive, Suite 2NE70, MSC 4811, Bethesda, MD, 20817
- ZIP Code
- 20817
- Solicitation Number
- NOI4059
- Response Due
- 4/19/2004
- Archive Date
- 5/4/2004
- Point of Contact
- Nataki McCowin, Purchasing Agent, Phone 301-402-6624, Fax 301-480-3695, - John Foley, Contracting Officer, Phone 301-402-2284, Fax 301-480-0689,
- E-Mail Address
-
nmccowin@niaid.nih.gov, jfoley@NIAID.NIH.GOV
- Small Business Set-Aside
- Total Small Disadvantage Business
- Description
- This is a combined synopsis/solicitation/notice of intent for commercial items prepared in accordance with the format in Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only notice of intent and a written notice of intent will not be issued. The National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) intends to negotiate on a sole source basis with Three Springs Scientific for African green monkeys of St Kitt origin, for respiratory Syncytial Virus Research. The Notice of Intent number is being issued as NOI4059. This Notice of Intent document and its incorporated provisions are those in effect through Federal Acquisition Circular FAC 2001-22. The NIAID, NIH, has a requirement to purchase approximately fifty (50) Cercocebus Aethiops (African green monkeys) St Kitts-PIV and approximately fifty (50) crates for transporting the African green monkeys. These items are to be delivered to the National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland via FOB Origin. This is a small disadvantage business and the North American Industry Classification System (NAICS) code for the acquisition is 112990 and the small business size standard is $0.75 million. The NIAID is involved in numerous projects for Bio-Defense vaccine development and most recently since the outbreak of Severe Acute Respiratory Syndrome (SARS). The NIAID is tasked with the main research in NIH on the study of SARS and to develop a vaccine. Studies in the NIAID focus primarily on viruses that play an important role in disease of the respiratory and gastrointestinal tracts, the liver, and the reticuloendothelial system. Currently, NIAID employs the techniques of viral genetics and molecular biology to express protective viral antigens and attenuate viral mutants that may prove useful for prevention of disease. A number of promising live attenuated viral vaccines and virus-specific immunotherapies are under development and evaluation. The NIAID conducts research directed toward defining the cause and epidemiology of medically important viral diseases and developing means for their control. NIAID engages in a wide range of research activities that extends from identification and antigenic characterization of viruses that cause systemic disease or acute disease of the respiratory and gastrointestinal tracts and the liver to basic molecular studies of viral structure, function, and genome organization. Scientists in the laboratory employ molecular biologic techniques to elucidate pathogenesis of disease as well as to develop purified subunit antigens and attenuated viral mutants for use in prevention of respiratory, gastrointestinal, hepatic, and systemic viral diseases. The approximately 50 listed Cercocebus Aethiops (African green monkeys of St Kitt origin) have been identified and serologically screened and are seronegative for Parainfluenza Viruses (PIV) 1, 2, 3 and HMPV. African green monkeys are the most sensitive for detecting and evaluating infection with PIV 1, 2, 3, and HMPV. RVS has increased needs for this species of non-human primate to test the potency of new lots of candidate PIV 1, 2, 3 vaccine, determine the dose response to this vaccine, explore the feasibility of post-exposure vaccination, examine cross-protection and measure the duration of protective immunity. NIAID studies are in anticipation of preparing PIV 1, 2, 3 vaccines for human use. Large numbers of African green monkeys are required so the lots of vaccines can be characterized before human clinical trials begin. Since Three Springs Scientific has supplied African green monkeys to NIAID in the past they must continue to provide these specific African green monkeys in order to compare data analyses and maintain consistency in the results. The necessary items are commercial as defined in FAR Part 12. FAR provisions and clauses that apply to this acquisition are FAR 52.212-1, Instructions to Offerors ? Commercial; FAR 52-212-2, Evaluation - Commercial Items Instructions to Offerors - Commercial Items; FAR 52.212-3, FAR Offeror Representations and Certifications - Commercial Items; FAR 52.212-4, Contract Terms and Conditions-Commercial Items; FAR 52.212-5, Contractor Terms and Conditions Required to Implement Statutes or Executive Orders - Commercial Items. Offerors must include with their offer a completed copy of the provisions of FAR 52.212-3, Offerors Representations and Certifications - Commercial Items. This action will be under the authority of Section 4202 Clinger Cohen Act of 1996, as set forth in FAR Part 6.302-1 AND HHSAR 306-302-1. Only one responsible source and no other supplies or services will satisfy agency requirements. Interested parties must be registered in the Central Contractor Registration (CCR). Interested parties may identify their interest and capability to respond to the requirement or submit proposals. This is not a request for competitive quotations. However, if any interested party believes they can perform the above requirements, they may submit a statement of capabilities. The statement of capabilities and any other furnished information must be in writing and must contain material in sufficient detail to allow NIAID to determine if the party can perform this requirement. Capability statements must be received in the contracting office by 4:00 PM EDT (Eastern Daylight Time), April 19, 2004. If you have any questions they must be submitted in writing to Nataki McCowin, Purchasing Agent, at nmccowin@niaid.nih.gov or by fax (301) 480-3695. For delivery through postal service the address is NIH/NIAID/AMOB, 10401 Fernwood Drive, Suite 2NE70, Room/2NE70B, MSC/4812, Bethesda, Maryland 20817-4812. A determination by the Government to not compete this proposed requirement shall be based upon responses to this notice and is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Notice of Intent number NOI4059 must be cited on all correspondence!!
- Place of Performance
- Address: National Institutes of Health,, Bethesda, Maryland
- Zip Code: 20892
- Country: USA
- Zip Code: 20892
- Record
- SN00567348-W 20040418/040416211905 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |